Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification

TipRanks07:05 ET

Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating

Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ.Price: 222.01, Change: +0.43, Percent Change: +0.19

MT Newswires06:24 ET

Jeito Capital Consolidates Its Support in CatalYm With a Renewed Participation in a $150 Million Financing

Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing

GlobeNewswire05:10 ET

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'

Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.

Benzinga21:36 ET

Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results

Seeking Alpha12:03 ET

Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A

Seeking AlphaJul 13 14:03 ET